【佳学基因检测】精神药物基因组学的前景

2022年用药指导基因检测价格一览表—目的

课题调研精神科个性化药物研究路径《精神与神经疾病基因突变度与预防策略的实施计划》《Biol Psychiatry》在. 2015 Jan 1;77(1):29-35.发表了一篇题目为《精神药物基因组学的前景》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Steven P Hamilton等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

遗传力、发病原因及精准治疗临床研究内容关键词：

细胞替代疗法,胚胎干细胞,胎儿神经组织,基因组编辑,诱导多能干细胞,神经干细胞

神经科用药指导基因检测临床应用结果

临床医生每天都在面对“个性化”药物，同时在个体患者中体验到毒性和药效的巨大差异。药物遗传学研究是发现药物反应和耐受性变异的 DNA 决定因素的平台。现在的研究主要集中在基因组上，因为它从分析单个基因开始。几种精神药物的治疗结果与特定的遗传变异弱相关，没有独立的复制。药物副作用显示出与遗传变异更强的关联，包括人类白细胞抗原位点与卡马西平诱导的皮肤病学结果和 MC4R 与非典型抗精神病药物体重增加。临床实施已被证明具有挑战性，障碍包括缺乏改变医疗保健所需的临床实用性的可复制前瞻性证据。最近的研究表明，有希望的方法可以减少将药物遗传学数据常规纳入临床护理的这些障碍。关键词：CYP2C19； CYP2D6;沮丧; GWAS；药物遗传学；精神分裂症。

神经及精神疾病及其并发征、合并征国际数据库描述：

Clinicians already face "personalized" medicine every day while experiencing the great variation in toxicities and drug efficacy among individual patients. Pharmacogenetics studies are the platform for discovering the DNA determinants of variability in drug response and tolerability. Research now focuses on the genome after its beginning with analyses of single genes. Therapeutic outcomes from several psychotropic drugs have been weakly linked to specific genetic variants without independent replication. Drug side effects show stronger associations to genetic variants, including human leukocyte antigen loci with carbamazepine-induced dermatologic outcome and MC4R with atypical antipsychotic weight gain. Clinical implementation has proven challenging, with barriers including a lack of replicable prospective evidence for clinical utility required for altering medical care. More recent studies show promising approaches for reducing these barriers to routine incorporation of pharmacogenetics data into clinical care.Keywords: CYP2C19; CYP2D6; Depression; GWAS; Pharmacogenetics; Schizophrenia.